Horizon Space Acquisition signs $2 billion business combination agreement with ArcheNova Biotech
Horizon Space Acquisition I Corp. has agreed to combine with ArcheNova Biotech in a transaction valuing the clinical-stage biotechnology company at approximately $2 billion.
The definitive business combination agreement, signed on 12 October and announced on 13 October, is intended to bring ArcheNova's extracellular vesicle and exosome-based therapeutic platforms into a publicly listed company.
The proposed combined business is expected to seek a Nasdaq listing, subject to shareholder approvals, regulatory requirements and customary closing conditions.
Field | Content |
Article Type | Deals |
Companies | Horizon Space Acquisition I Corp.; ArcheNova Biotech |
Deal Type | Definitive business combination agreement |
Transaction Structure | Business combination involving a special purpose acquisition company and a clinical-stage biotechnology company |
Implied Company Valuation | Approximately $2 billion |
Cash Consideration | Not specified in the supplied announcement summary |
Transaction Status | Definitive agreement signed; completion pending |
Agreement Date | 12 October 2026 |
Announcement Date | 13 October 2026 |
Target Company | ArcheNova Biotech |
Technology/Modality | Mesenchymal stromal cell-derived extracellular vesicles and exosome-based therapeutic platforms |
Development Stage | Clinical-stage biotechnology |
Expected Listing | Nasdaq, subject to transaction completion and applicable requirements |
Closing Conditions | Required approvals and customary closing conditions |
Geography | United States capital markets |
What Happened | Horizon Space Acquisition I Corp. and ArcheNova Biotech entered a definitive business combination agreement valuing ArcheNova at approximately $2 billion. |
Why It Matters | The proposed transaction could provide ArcheNova with access to public capital markets to support development of its extracellular vesicle and exosome-based therapeutic programmes. |
Supporting Context | The $2 billion figure represents the proposed transaction valuation rather than a cash acquisition payment. |
Strategic Rationale | The combination is intended to establish a publicly listed biotechnology company focused on ArcheNova's therapeutic technology platforms. |
Potential Impact | Completion could expand ArcheNova's financing opportunities and public-market visibility, subject to the final transaction structure and available capital. |
Key Takeaway | ArcheNova Biotech has agreed to a proposed $2 billion SPAC business combination with Horizon Space Acquisition I Corp. |
What to Watch | Shareholder approvals, regulatory filings, transaction closing, final financing terms and the proposed Nasdaq listing. |
Primary Source | Horizon Space Acquisition I Corp.; SEC filing |
Relevant Date | 13 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare